ASBPW — ASPIRE BIOPHARMA HLDGS INC
As of Q2 2026, 3 SEC-registered investment managers reported holding ASBPW (ASPIRE BIOPHARMA HLDGS INC) in their latest 13F filings, with a combined reported value of $11.86K across 575.00K shares. That is -23.1% by share count (-173.00K shares) versus the previous quarter, while reported value moved -0.3%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 1 trimmed. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
ASBPW is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
| Fund | Quarter | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|---|
| Millennium Management history | Q2 2026 | 275.00K | $5.50K | 0.00% | Hold |
| D. E. Shaw & Co history | Q2 2026 | 200.00K | $4.10K | 0.00% | Hold |
| JPMorgan Chase & Co history | Q2 2026 | 100.00K | $2.26K | 0.00% | Reduce |
New Positions (Q2 2026)
No fund opened a new position this quarter.
Fully Exited (vs previous quarter)
No tracked fund fully exited this quarter.
Fund Position History — shares by quarter (top 3 funds)
| Fund | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| Millennium Management | 275.00K | 275.00K | 275.00K | 275.00K | 275.00K | 275.00K |
| D. E. Shaw & Co | 200.00K | 200.00K | 200.00K | 200.00K | 200.00K | 200.00K |
| JPMorgan Chase & Co | 100.00K | 100.00K | 100.00K | 100.00K | 273.00K | 100.00K |